E-7050 aphazoline Hydrochloride Suplatast tosilate-treated DCs has an

Suplatast tosilate-treated DCs has an impaired capacity to stimulate CD4(+) T cells to produce IFN-gamma and IL-5

Langguth P

The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation

InChi: InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67

E-7050 aphazoline Hydrochloride Suplatast tosilate-treated DCs has anGolvatinib, also known as E7050, is an orally bioavailable dual kinase inhibitor of c Met (hepatocyte growth factor receptor) and VEGFR 2 (vascular endothelial growth factor receptor 2) tyrosine kinases with potential antineoplastic activity. c Met VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c Met and VEGFR 2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases.